Companies › Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Belzutifan (PT2977) Endothelial PAS domain-containing protein 1 inhibitor | EPAS1 | Phase 2 | Renal Cell Carcinoma (RCC); VHL - Von Hippel-Lindau Syndrome; Advanced Solid Tumors; ccRCC | Nov 2026 |
| MK-3795 HIF-2α inhibitor | HIF2A | Phase 1 | ccRCC | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02974738 | Belzutifan (PT2977) | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2026 |
| NCT02293980 | Belzutifan (PT2977) | Phase 1 | ccRCC | Oncology | Nov 2026 |
| NCT02293980 | MK-3795 | Phase 1 | ccRCC | Oncology | Nov 2026 |
| NCT03634540 | Belzutifan (PT2977) | Phase 2 | Renal Cell Carcinoma (RCC) | Oncology | Feb 2027 |
| NCT03401788 | Belzutifan (PT2977) | Phase 2 | VHL - Von Hippel-Lindau Syndrome | Oncology | Apr 2027 |
Vividion Therapeutics Neonc Technologies GI Innovation iTeos Therapeutics EpicentRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.